BIOS Capital Management’s Lantern Pharma LTRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$238K Sell
235,895
-13,502
-5% -$32.5K 0.7% 5
2026
Q2
$1.04M Sell
249,397
-615,038
-71% -$1.8M 2.5% 5
2026
Q1
$1.18M Sell
864,435
-145,072
-14% -$406K 2.24% 5
2025
Q4
$3.06M Sell
1,009,507
-6,208
-0.6% -$23.1K 3.7% 4
2025
Q3
$4.42M Sell
1,015,715
-60,237
-6% -$251K 4.97% 4
2025
Q2
$3.4M Sell
1,075,952
-131,757
-11% -$445K 4.68% 3
2025
Q1
$4.28M Hold
1,207,709
– – 5.4% 2
2024
Q4
$3.85M Buy
+1,207,709
New +$4.14M 4.09% 4

Other funds holding LTRN

BIOS Capital Management's LTRN Position: Q3 2026 in Review

BIOS Capital Management reduced its Lantern Pharma (LTRN) stake by 5.4% in Q3 2026, selling an estimated $32.5K and leaving 235,895 shares worth $238K. The position accounts for 0.7% of the portfolio, ranked #5.

BIOS Capital Management first reported a position in LTRN in Q4 2024 and has held it in 8 quarters since. The position peaked at $4.42M in Q3 2025. 36 funds tracked by Wall St. Rank hold LTRN as of Q3 2026.

  • BIOS Capital Management held 235,895 shares of Lantern Pharma worth $238K as of Q3 2026.
  • BIOS Capital Management sold 13,502 Lantern Pharma shares in Q3 2026, an estimated $32.5K.
  • Lantern Pharma made up 0.7% of BIOS Capital Management's portfolio in Q3 2026, its #5 holding.
  • BIOS Capital Management first reported a position in Lantern Pharma in Q4 2024 and has held it in 8 quarters since.
  • BIOS Capital Management's Lantern Pharma position peaked at $4.42M in Q3 2025.
  • 36 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2026.

Based on BIOS Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.